Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company has formed an exclusive licensing agreement develop a potential coronavirus treatment, TNX-3500, from OyaGen, Inc. a pre-clinical biotechnology research company. Dr Lederman says in TNX-3500 is '65 times more potent' than Gilead's Remdesivir, in-vitro, at inhibiting the coronavirus. He adds the group is very excited to move TNX-3500 into animal studies, and later clinical testing in humans.
Tonix Pharmaceuticals forms exclusive licensing agreement develop a potential coronavirus treatment
